Our Solution
Designed to Treat People with Diabetes
Where They Are in their Journey
Why Current Diabetes Management Isn't Good Enough
Fear drives much of diabetes management today. One in three people with Type 1 diabetes intentionally keep their glucose high – sacrificing long-term health to avoid low blood sugars. The consequences are can be significant:
Long-term Impact:
- Less than 1/3 of diabetes patients achieve glucose targets
- Loss of ~13 years of life expectancy
- Most common cause of blindness, kidney failure, and lower limb amputations
Daily Risks:
- Hypoglycemia can be a daily occurrence with current treatments
- ~1.4M emergency hospital visits/hospitalizations per year (USA)
- 4-10% of deaths in T1D are attributed to acute hypoglycemia
- Some people are “hypo unaware” and don’t realize their blood sugar is dropping dangerously low
The Abvance Solution: Beyond 'Good Enough'
Abvance’s lead program, ABV101 isn’t just another insulin therapy—it’s a potential lifeline. Developed through cutting-edge research at Vanderbilt University, ABV101 was designed to address the greatest fear of insulin therapy: hypoglycemia. ABV101 was designed to give people a better tool to balance their insulin treatment with something that could reduce the daily anxiety of life-threatening low blood sugar episodes.
ABV101: Human Proof of Concept
ABV101 was designed to work by combining insulin and glucagon, at a fixed molar ratio, to provide a safety net against low blood sugar. Ultimately, with a rigorous pre-clinical and clinical data package, Abvance is committed to bringing ABV101 to the market to give people with diabetes, those who love them, and healthcare providers another tool in the fight against diabetes.
Potential:
Patient Impact:
- Better glucose control without fear of crashes
- No new devices or behavioral changes needed
- Simplified daily management
- Improved quality of life
Abvance is not just stopping with the innovation in ABV101. We are working on a robust pipeline of products that can be leveraged across the diabetes treatment journey based on the innovative mechanism of action developed at Vanderbilt.
Be Part of the Solution
For 10 million patients in the US and EU, insulin therapy is more than a treatment – it’s a daily struggle. ABV101 offers them something they’ve long deserved: peace of mind. Are you ready to be part of this breakthrough that not only redefines insulin therapy but also restores hope to patients worldwide? Learn more about how ABV101 and the whole Abvance pipeline can change lives.
All information on this web site relates to investigational new drugs which are limited by Federal law to investigational use only. Abvance does not make any claims to safety or efficacy as to any investigational product. No product discussed on this web site has been approved by any regulatory agency as safe or effective. The purpose of this web site is to provide information to potential industry partners and potential institutional investors.
Website & Branding by Mile End Digital